Trinity Biotech Buys Centocor's UK Unit
Trinity Biotech, which is based in Dublin, Ireland, has agreed topurchase the UK infectious diseases business of the US company Centocor. Trinity will pay $5.5 million in cash and loan notes.
The UK unit develops, manufactures and markets infectious disease diagnostic tests in micro titer enzyme immunoassay plate format. Trinity says that the firm's product line is complementary to its own existing EIA range, and will enable it to access new and significant market segments.
Trinity also points out in a statement that Centocor has recently developed a test for Chagas disease, which has "significant market potential."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze